News Daily News Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab Michael O'Riordan February 05, 2025
News Daily News Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER Michael O'Riordan February 08, 2024
News Daily News No Safety Concerns Seen With Inclisiran in Large ORION Analysis Michael O'Riordan December 06, 2023
News Daily News Ezetimibe Plus Moderate-Dose Statins May Aid Compliance in the Elderly Yael L. Maxwell April 03, 2023
News Daily News Nonfatal MI Not a Death Surrogate in Cardiology: Meta-analysis Caitlin E. Cox October 27, 2021
News Daily News Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES Michael O'Riordan May 04, 2020
News Daily News Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES Michael O'Riordan August 26, 2019
News Daily News PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction Michael O'Riordan April 29, 2019
News Daily News ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom Michael O'Riordan November 07, 2018
News Daily News Starting Low and Going Lower: Some Benefit to Very Low LDL Levels Michael O'Riordan August 02, 2018
News Daily News LPA Variants Linked With CHD Events in Statin-Treated Patients Michael O'Riordan May 03, 2018
News Daily News The Higher the LDL, the Bigger the Mortality Benefit of Intensive Therapy: Meta-analysis Michael O'Riordan April 20, 2018
News Daily News Alirocumab Ban Reversed, New Trial Ordered in PCSK9 Patent Dispute Michael O'Riordan October 10, 2017
News Daily News ACC Updates Recommendations for Non-statin Therapy Use for LDL-Cholesterol Lowering in Secondary Prevention Yael L. Maxwell September 06, 2017
News Daily News Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint Michael O'Riordan February 03, 2017
News Daily News How Low Can Cholesterol Go? Safety Not in Limbo for Patients With Very Low LDL on Alirocumab, Study Shows Yael L. Maxwell January 31, 2017